Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $77.71

ANI Pharmaceuticals, Inc. (NASDAQ:ANIPGet Free Report) has received an average rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $77.71.

Several brokerages have recently issued reports on ANIP. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th.

Get Our Latest Stock Report on ANI Pharmaceuticals

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $57.94 on Friday. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -105.35 and a beta of 0.74. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a 50 day moving average price of $57.08 and a 200 day moving average price of $58.23.

Insider Activity

In other news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 42,781 shares of company stock valued at $2,465,372. Insiders own 12.70% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ANIP. US Bancorp DE increased its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV raised its position in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after buying an additional 579 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $166,000. Finally, HighTower Advisors LLC purchased a new stake in ANI Pharmaceuticals in the 3rd quarter worth approximately $222,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

(Get Free Report

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Featured Stories

Analyst Recommendations for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.